Pulmonary Hypertension KOL Interview - US #1

This interview with a US-based key opinion leader (KOL) provides insights into current prescribing habits in WHO groups 1-5, key marketed brands and their placement in the treatment algorithm, and expectations for late-phase pipeline therapies for pulmonary hypertension. Key assets highlighted include Tyvaso, Tyvaso DPI, Yutrepia, Adempas, Letairis, Opsumit, Orenitram, Uptravi, Remodulin, Adcirca, sotatercept, INOpulse, and ralinepag.